NCT01422330 - A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients | Biotech Hunter

Enrollment

211

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions

Human Immunodeficiency Virus (HIV) Infection

Interventions

DRUG

Etravirine

Type=exact number, unit=mg, number=100, form=tablet, route=oral use, 2 tablets. Type=exact number, unit=mg, number=200, form=tablet, route=oral use, 1 tablet. The drug is taken twice a day, after meals.

Trial Locations (42)

Unknown

Phoenix

Beverly Hills

North Hollywood

Fort Laudersale

Hialeah

Miami

Springfield

Akron

Longview

Buenos Aires

Rosario

Le Kremlin-Bicêtre

Paris

Guatemala City

Guadalajara

México

Iquitos

Lima

San Juan

Brasov

Constanța

Craiova

Timișoara

Krasnodar

Moscow

Saint Petersburg

Smolensk

Volgograd

Voronezh

Bloemfontein

Boksburg

Dundee

Durban

Johannesburg

Newtown

Port Elizabeth

Pretoria

Westdene Johannesburg Gauteng

Donetsk

Kyiv

Luhansk

Sumy

All Listed Sponsors

lead

Janssen R&D Ireland

INDUSTRY